BRCA1 and non-small cell lung carcinoma: The results support further prospective trials testing for BRCA1/2 mutations in NGS panels of NSCLC patients and treatment with PBC and PARPi for patients with p-BRCA and in cases of carriers of BRCA who develop NSCLC.